Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 10:35 AM ET

Biotechnology

Company Overview of Theraclone Sciences, Inc.

Company Overview

Theraclone Sciences, Inc., a discovery-stage biopharmaceutical company, engages in the discovery and development of monoclonal antibody therapeutics for the treatment of infectious diseases and inflammation. The company focuses on identifying rare fully human antibodies from immunologically relevant human subjects by using its proprietary antibody discovery technology, I-STAR (In-Situ Therapeutic Antibody Rescue). It has a portfolio of antibody programs at preclinical and clinical development stage targeting various medical conditions, including influenza, HIV, other bacterial targets, breast cancer, and infectious disease-associated cancers. Theraclone Sciences, Inc. has strategic collabora...

1124 Columbia Street

Seattle Life Sciences Building

Suite 300

Seattle, WA 98104

United States

Founded in 2004

Phone:

206-805-1600

Fax:

206-805-1699

Key Executives for Theraclone Sciences, Inc.

Chief Executive Officer and Director
Age: 55
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Theraclone Sciences, Inc. Key Developments

Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM

Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015

Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015. Venue: The Waldorf Astoria, New York, New York, United States. Presentation Date & Speakers: Feb-10-2015, Clifford J. Stocks, Chief Executive Officer and Director.

Theraclone Sciences Announces Licenses Agreement with Gilead Sciences

Theraclone Sciences, Inc. has entered into a license agreement with Gilead Sciences, Inc. to develop and commercialize products incorporating Theraclone's broadly neutralizing human immunodeficiency virus (HIV)-antibodies for therapeutic applications in HIV. Both the companies are based in the US. Under the terms of the transaction, Theraclone will receive an upfront payment and is eligible to receive additional payments based upon achievement of certain development and commercialization milestones.

Similar Private Companies By Industry

Company Name Region
Mergen Ltd. United States
Vivo Biosciences Inc. United States
uBiome, Inc. United States
Profectus Biosciences, Inc. United States
Gene Solutions LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Theraclone Sciences, Inc., please visit www.theraclone-sciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.